Abiraterone acetate by Tavanta Therapeutics for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 7, 2024
Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.
Let's personalize your content